Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Alkermes Strategy After Antidepressant Failures Doubted By Wall Street

This article was originally published in The Pink Sheet Daily

Executive Summary

With a pair of Phase III failures for its major depression disorder candidate ALKS-5461, Alkermes is pinning hopes on a third pivotal trial plus ad hoc analysis of a failed study – a strategy analysts find unlikely to prevail.


Related Content

Will Alkermes Data Package Support ALKS 5461 Approval?
Alkermes Says New Aripiprazole Is Just The Start Of A Blockbuster Streak


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst